



WHAT IS CLAIMED IS:

1. A pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels in a mammal comprising the following compounds:


Genus A,



Genus B, and



Genus C,



wherein X and Y are independently selected from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF₃, OCF₃, CONH₂, CONHR and NHCOR₁;

wherein R is selected from the group consisting of H, CH₃, C₂H₅, C₃H₇, C₄H₉, CH₂Ph, CH₂C₆H₄-F(p-), COCH₃, CO₂CH₂CH₃, aminoalkyl and dialkylaminoalkyl; and





wherein R_1 and R_2 are independently selected from the group consisting of H, aryl, heteroaryl, thiophene, pyridyl, thiazolyl, isoxazolyl, oxazolyl, pyrimidinyl, substituted aryl, substituted heteroaryl, substituted thiophene, substituted pyridyl, substituted thiazolyl, substituted isoxazolyl, substituted oxazolyl, cycloaryl, cycloheteroaryl, quinolinyl, isoquinolinyl, substituted cycloaryl, substituted cycloheteroaryl, substituted quinolinyl, substituted isoquinolinyl, multi-ring cycloaryl, multi-ring cycloheteroaryl, benzyl, heteroaryl-methyl, substituted benzyl, substituted heteroaryl-methyl alkyl, dialkylaminoalkyl, cycloalkyl, cycloalkyl containing 1-3 heteroatoms, substituted cycloalkyl, substituted cycloalkyl containing 1-3 heteroatoms, multi-ring cycloalkyl, multi-ring cycloalkyl containing 1-3 heteroatoms, fused-ring aliphatic, fused-ring aliphatic containing 1-3 heteroatoms, cyclopropyl, substituted cyclopropyl, cyclobutyl, substituted cyclobutyl, cyclopentyl, pyrrole, piperidine, substituted cyclopentyl, cyclohexyl, substituted cyclohexyl, cycloheptyl, substituted cycloheptyl, bicycloheptyl, substituted pyrrole, substituted piperidine, bicyclooctyl, bicyclononyl, substituted bicycloalkenyl, adamantyl, and substituted adamantyl, wherein at least one of R_1 and R_2 are aromatic groups or heteroaromatic groups.





2. The pharmaceutical composition of Claim 1, wherein the substituents on said substituted aryl, substituted heteroaryl, substituted thiophene, substituted pyridyl, substituted thiazolyl, substituted isoxazolyl, substituted oxazolyl, substituted cycloaryl, substituted cycloheteroaryl, substituted quinolinyl, substituted isoquinolinyl, substituted benzyl, substituted heteroaryl-methyl alkyl, substituted cycloalkyl, substituted cycloalkyl containing 1-3 heteroatoms, substituted cyclopropyl, cyclobutyl, substituted cyclobutyl, substituted cyclopentyl, substituted cyclohexyl, cycloheptyl, substituted cycloheptyl, bicycloheptyl, substituted pyrrole, substituted piperidine, bicyclooctyl, bicyclononyl, substituted bicycloalkenyl, adamantyl, and substituted adamantyl are independently selected from the group consisting of alkyl, aryl, CF_3 , CH_3 , OCH_3 , OH, CN, $CONH_2$, $CONHR$, $CONR_1R_2$, COOR and COOH.

3. The pharmaceutical composition of Claim 1, further comprising at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.

4. The pharmaceutical composition of Claim 3, wherein said at least one additional ingredient is selected from the group consisting of a short-acting β_2 -adrenergic agonist, a long-acting β_2 -adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.










5. The pharmaceutical composition of Claim 1, wherein the compound is selected from the group consisting of:





Sub
A2
cont.

0993054-101601













Sub
A2
cont.

0903054-10401

Sub
A2
cont.

FIG. 10 "450E3650"








6. A method for treating or preventing an allergic reaction in a mammal wherein said reaction is caused by an increase in IgE levels comprising administering an IgE-suppressing amount of at least one compound of Claim 1.

7. The method of Claim 6, further comprising administering in conjunction with at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.

8. The method of Claim 7, wherein said additional ingredient is selected from the group consisting of a short-acting β_2 -adrenergic agonist, a long-acting β_2 -adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

9. The method of Claim 6, wherein the compound is selected from the group consisting of:















Sub
A3
cont.

FOR "4502260"

Sub
A³
Cont.

0993064-10160










10. A method for treating or preventing asthma in a mammal comprising administering an IgE-suppressing amount of at least one compound of Claim 1.











11. The method of Claim 10 further comprising administering in conjunction with at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.

12. The method of Claim 11, wherein said additional ingredient is selected from the group consisting of a short-acting β_2 -adrenergic agonist, a long-acting β_2 -adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

13. The method of Claim 10, wherein the compound is selected from the group consisting of:







093034-1030

add
A4